Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

In the last few years, large Phase III trials showed improvements in survival and outcomes and led to the approval of a CYP17 inhibitor (abiraterone), an androgen receptor antagonist (enzalutamide ...

Abiraterone CYP17 (secondary androgen production) Approved by the US FDA for the treatment of mCRPC Improved median OS in mCRPC after chemotherapy (14.8 vs 10.9 months; HR: 0.65; p < 0.001 ...

We report here a molecular modeling investigation of steroidal and nonsteroidal inhibitors of human cytochrome P450 17α-hydroxylase-17,20-lyase (CYP17). Using the pharmacophore perception technique, ...

Estrogen plays a role in the pathogenesis of leiomyoma. The CYP17 gene codes for the cytochrome P450c17alpha enzyme, which is involved in the biosynthesis of estrogen. Our aim was to investigate if ...

Abstract: CYP17 (17α-hydroxylase/17, 20-lyase) has been viewed as a critical enzyme for the biosynthesis of gonadal and adrenal steroids in vertebrates. According to a reported CYP17 gene of ...

New Delhi: MSN Laboratories has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct a bioequivalence study of ...

At the recommended dose, Zytiga maximally inhibits CYP17 hydroxylase and CYP17 lyase. Propella has designed its candidate to provide the level of abiraterone needed to block CYP17 lyase for 12 weeks.

The team, involving Professor Mike Jarman, Dr Elaine Barrie and Professor Gerry Potter, as well as many other collaborators including Professor Stephen Neidle and Dr Charles Laughton, set out to ...

Furthermore, gonadal autoimmunity markers prevail in APS1 and APS2 APOI women, while the percentage of sera positive for StC-Abs and CYPscc-Abs/CYP17-Abs falls in women with non-AAD-associated APOI, ...

The aim of this study was to determine whether seviteronel (INO-464), a novel CYP17 lyase inhibitor and AR antagonist, is able to radiosensitize AR-positive (AR+) TNBC models. In cell viability assays ...